Sponsor announces Tavneos discontinuation

Prescribers are being urged not to initiate treatment with Tavneos (avacopan) in new patients, with the drug to be withdrawn from the Australian market next year  CSL Seqirus is set to discontinue its antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis drug, Tavneos, from 31 March 2027, the Therapeutic Goods Administration says.   The regulator previously announced it was